Triptan therapy impacts health and productivity.
New sumatriptan users in a California health plan were surveyed on the impact of migraine using a newly developed migraine impact measure, the Headache Impact Test-6. Productivity and satisfaction with migraine therapy also were assessed. After sumatriptan was initiated, participants reported significantly fewer workdays missed, fewer days worked with headache, and greater productivity while headache symptoms were present. In addition, almost 50% less members used narcotics/opioids, while the frequency, duration, and severity of migraines decreased. Initiation of sumatriptan therapy is associated with improvements in absenteeism and presenteeism, clinical outcomes (Headache Impact Test-6), and satisfaction. The benefits of triptan therapy extend to the employer, who sees a decrease in lost productivity, fewer emergency room visits, and less narcotics use in employees with migraine. Managed care organizations that provide this pharmacotherapy may foster greater satisfaction among members and employer customers.
GlaxoSmithKline, Research Triangle Park, North Carolina 27709-3398, USA. Mary.B.Weaver@gsk.com
Mary Brun
MB
Weaver
John I
JI
Mackowiak
Paul G
PG
Solari
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D004526:Efficiency; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D016272:Occupational Health; D011446:Prospective Studies; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D018170:Sumatriptan / Q000627:therapeutic use*
D017366:Serotonin Receptor Agonists; D018170:Sumatriptan